This article is more than 5 years old. Information may no longer be current.

Sun Pharma receives FDA approval for generic allergic conjunctivitis treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MUMBAI, India — The U.S. Food and Drug Administration has approved Sun Pharma's abbreviated new drug application to market a generic formulation of azelastine ophthalmic solution 0.05% for treating ocular itching secondary to allergic conjunctivitis, the company announced in a press release.

The solution is therapeutically equivalent to Optivar (azelastine HCl ophthalmic solution 0.05%, Meda), which is marketed by MedPointe Pharmaceuticals in the U.S. and Canada.

Follow OSNSuperSite.com on Twitter.